MA31795B1 - Molécules et méthodes pour moduler un constituant de complément - Google Patents

Molécules et méthodes pour moduler un constituant de complément

Info

Publication number
MA31795B1
MA31795B1 MA32801A MA32801A MA31795B1 MA 31795 B1 MA31795 B1 MA 31795B1 MA 32801 A MA32801 A MA 32801A MA 32801 A MA32801 A MA 32801A MA 31795 B1 MA31795 B1 MA 31795B1
Authority
MA
Morocco
Prior art keywords
methods
particles
modification
supplement component
supplement
Prior art date
Application number
MA32801A
Other languages
Arabic (ar)
English (en)
Inventor
Bijan Etemad-Gilbertson
Braydon Charles Guild
Mark Taylor Keating
Yong-In Kim
Lloyd B Klickstein
Dmitri Mikhailov
Mariusz Milik
Michael Roguska
Igor Splawski
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31795B1 publication Critical patent/MA31795B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des compositions se liant aux épitopes c3b ainsi que des méthodes d'utilisation de ces compositions.
MA32801A 2007-11-02 2010-04-30 Molécules et méthodes pour moduler un constituant de complément MA31795B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98495107P 2007-11-02 2007-11-02
PCT/EP2008/064809 WO2009056631A2 (fr) 2007-11-02 2008-10-31 Molécules et méthodes pour moduler un constituant de complément

Publications (1)

Publication Number Publication Date
MA31795B1 true MA31795B1 (fr) 2010-10-01

Family

ID=40343498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32801A MA31795B1 (fr) 2007-11-02 2010-04-30 Molécules et méthodes pour moduler un constituant de complément

Country Status (21)

Country Link
US (1) US20090175875A1 (fr)
EP (1) EP2207807A2 (fr)
JP (1) JP2011503024A (fr)
KR (1) KR20100067681A (fr)
CN (1) CN101848937A (fr)
AR (1) AR069130A1 (fr)
AU (1) AU2008320820A1 (fr)
CA (1) CA2703911A1 (fr)
CL (1) CL2008003241A1 (fr)
CO (1) CO6270341A2 (fr)
CR (1) CR11361A (fr)
EA (1) EA201000717A1 (fr)
IL (1) IL204722A0 (fr)
MA (1) MA31795B1 (fr)
MX (1) MX2010004833A (fr)
PE (1) PE20091388A1 (fr)
SV (1) SV2010003556A (fr)
TN (1) TN2010000169A1 (fr)
TW (1) TW200924795A (fr)
WO (1) WO2009056631A2 (fr)
ZA (1) ZA201002335B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149567A2 (fr) 2006-06-21 2007-12-27 Musc Foundation For Research Development Ciblage du facteur h du système complémentaire destiné au traitement de maladies
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
ES2425768T3 (es) 2007-11-02 2013-10-17 Novartis Ag Moléculas de unión a nogo-a mejoradas y uso farmacéutico de las mismas
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CA2795311A1 (fr) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Traitement de l'hemoglobinurie paroxystique nocturne, des anemies hemolytiques et des etats pathologiques impliquant l'hemolyse intravasculaire et extra-vasculaire
EP2569332B1 (fr) 2010-05-14 2019-01-09 The Regents of the University of Colorado, A Body Corporate Groupes de ciblage des récepteurs 2 du complément (cr2) améliorés
KR20130036276A (ko) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
CA2821067C (fr) * 2010-11-29 2019-06-04 Novelmed Therapeutics, Inc. Neoanticorps pour le diagnostic d'une lesion tissulaire
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
KR102192596B1 (ko) 2013-08-07 2020-12-18 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
EP3092252B1 (fr) 2014-01-08 2019-09-18 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anticorps ciblant une protéine c3d du complément déposée sur une surface cellulaire, et utilisation de celui-ci
WO2016033382A1 (fr) * 2014-08-27 2016-03-03 Capnia, Inc. Procédés d'administration d'immunoglobulines
BR112018012844A2 (pt) * 2015-12-23 2018-12-04 Greenovation Biotech Gmbh polipeptídeos para inibir a ativação de complemento
MY196220A (en) 2016-06-14 2023-03-23 Regeneron Pharma Anti-C5 Antibodies and uses Thereof
EP3526248A4 (fr) 2016-10-17 2020-07-08 Musc Foundation for Research Development Compositions et méthodes de traitement d'une lésion du système nerveux central
WO2019118556A1 (fr) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Associations d'anticorps anti-c5 et utilisations associées
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用
US20240132617A1 (en) * 2022-09-20 2024-04-25 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5932217A (en) * 1991-05-03 1999-08-03 The Rockefeller University Peptides which inhibit adhesion between leukocytes and endothelial cells
AU6397796A (en) * 1995-06-29 1997-01-30 Medical Biology Institute Method for identifying peptides that affect protein-protein interactions and complement-modulating peptides
WO2002088750A2 (fr) * 2001-05-02 2002-11-07 Oxford Glycosciences (Uk) Ltd Proteines, genes et leur utilisation dans le cadre du diagnostic et du traitement du cancer du sein
US7042716B2 (en) * 2003-08-25 2006-05-09 Simon John Edward Shearman Ergonomic pull-out computer housing
WO2006012621A2 (fr) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions et procedes de regulation de la voie interne
WO2006042252A2 (fr) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Proteines regulatrices du complement viral pour troubles de la vue
WO2007047796A2 (fr) * 2005-10-17 2007-04-26 Institute For Systems Biology Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation
US7327547B1 (en) * 2006-01-20 2008-02-05 Epstein Barry M Circuit element and use thereof
MX2009013082A (es) * 2007-06-07 2010-01-15 Genentech Inc Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.

Also Published As

Publication number Publication date
KR20100067681A (ko) 2010-06-21
CA2703911A1 (fr) 2009-05-07
AU2008320820A1 (en) 2009-05-07
EA201000717A1 (ru) 2010-12-30
TW200924795A (en) 2009-06-16
CN101848937A (zh) 2010-09-29
CO6270341A2 (es) 2011-04-20
MX2010004833A (es) 2010-05-27
JP2011503024A (ja) 2011-01-27
SV2010003556A (es) 2011-03-23
IL204722A0 (en) 2010-11-30
CL2008003241A1 (es) 2009-07-31
AR069130A1 (es) 2009-12-30
WO2009056631A2 (fr) 2009-05-07
EP2207807A2 (fr) 2010-07-21
ZA201002335B (en) 2011-02-23
CR11361A (es) 2010-06-01
TN2010000169A1 (en) 2011-11-11
PE20091388A1 (es) 2009-09-24
WO2009056631A3 (fr) 2009-08-20
US20090175875A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
MA31795B1 (fr) Molécules et méthodes pour moduler un constituant de complément
MA34641B1 (fr) Anticorps anti-il-23
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
WO2009009041A3 (fr) Compositions et procédés permettant de moduler une cascade de kinases
SG144900A1 (en) Soot dispersants and lubricating oil compositions containing same
WO2008002674A3 (fr) Compositions bicycliques et procédés de modulation d'une cascade de kinases
MX2008002278A (es) Acido graso de aceite de bogol bajo en azufre.
MY142334A (en) Fertilizer-compatible composition
WO2012068105A3 (fr) Compositions et leurs utilisations pour convertir des contaminants
UA104005C2 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
MA34881B1 (fr) Anticorps et immunoconjugués anti-mésothéline
TW200719892A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MA33198B1 (fr) Anticorps anti-her di-spécifiques
MX2010000649A (es) Estructuras fibrosas y metodos para elaborarlas.
CO6571886A2 (es) Antagonistas de pcsk9
TN2010000213A1 (en) Wise binding antibodies and epitopes
MX2009013593A (es) Formulaciones de anticuerpos.
MX2010007481A (es) Composiciones de siloxano.
TW200724140A (en) Hydantoin compounds
WO2006078886A3 (fr) Composes et compositions utilises comme modulateurs de la voie de signalisation wnt
MX2009013354A (es) Compuestos de triarilo y composiciones que los contienen.
MX2009004757A (es) Moduladores de regeneracion neuronal.
MX2009013170A (es) Particulas de silice y metodos para prepararlas y utilizarlas.
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof